Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN) announced the completion of a milestone in its collaboration with Google Cloud, involving the integration of agentic AI systems into its ChemPass AI™ platform for small-molecule discovery.

According to a press release, the integration uses Google's Gemini models and Gemini Enterprise Agent Platform to enable earlier profiling of biological and clinical success criteria during the drug discovery process. The system is designed to evaluate structural, biological, chemical, and clinical data through autonomous AI agents to identify requirements a molecule must meet before significant resources are committed.

The company said the enhanced platform is intended to address challenges common in small-molecule development, including high attrition rates, delayed identification of downstream obstacles, and inefficient allocation of research and development resources. Many of these criteria are traditionally assessed only in later development stages.

Boaz Maoz, Managing Director of Google Cloud Israel, said: "By using our Gemini models and embarking on agentic AI, Evogene is positioned to innovate and significantly accelerate the discovery of new molecules, demonstrating the transformative power of AI in streamlining complex biological and chemical research."

Ofer Haviv, President and CEO of Evogene, stated: "By integrating advanced AI agents into ChemPass AI™, we believe we can generate richer target profiles earlier in discovery. This is intended to allow us to anticipate downstream requirements and prioritize high-potential candidates before committing significant resources."

Evogene develops computational tools for small-molecule design targeting pharmaceutical and agricultural applications. The company is based in Rehovot, Israel.